Abstract
Background
To reduce recurrence or progression of tumor, NCCN guidelines recommend repeat transurethral
resection of bladder tumors (reTURB) for non-muscle-invasive bladder cancer (NMIBC).
The study aims to compare the impact of initial TURB and reTURB on the rate of residual
or upstaging tumors and short-term and long-term survival outcomes of T1 bladder cancer
(BC).
Materials and methods
We searched through several public database, including PubMed, Embase, Ovid Medline
and Ovid EBM Reviews - Cochrane Central Register of Controlled Trials. The latest
search time was October 2021.
Results
In general, 68 articles were involved. Short-term RFS (1-year and 3-year) of reTURB
group was better compared with TURB group in T1 patients. The pooled RR were 1.10
(95%CI: 1.01–1.19) and 1.15 (95%CI: 1.03–1.28), respectively. While reTURB did not
improve long-term RFS (5-year, 10-year, 15-year) in T1 patients. The pooled RR were
1.12 (95%CI: 0.97–1.30), 1.11 (95%CI: 0.82–1.50) and 1.37 (95%CI: 0.50–3.74), respectively.
Analysis of PFS, OS and CSS demonstrated similar outcomes with RFS. We found that
about two-thirds of samples contained detrusor. The residual tumor rate in stage T1
was 0.48 (95%CI: 0.42–0.53). While the rate of upstaging in stage T1 was 0.10 (95%CI:
0.07–0.13).
Conclusions
In conclusion, reTURB might provide short-term survival benefits for T1 BC, but it
was not the same for long-term outcomes. The residual and upstaging rates of T1 BC
in reTURB were around 50% and 10%, respectively. Our study might be conducive to clinically
informed consents when patients expressed their concerns about the necessity of reTURB
and its impact on diagnosis, treatment and prognosis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology and risk factors of urothelial bladder cancer.Eur Urol. 2013; 63: 234-241
- Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology.J Natl Compr Cancer Netw. 2020; 18: 329-354
- Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review.Eur Urol. 2018; 73: 925-933
- Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.Eur Urol. 2009; 56: 903-910
- Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.Eur Urol. 2010; 57: 300-309
- European association of Urology guidelines on non-muscle-invasive bladder cancer (TaT 1 and carcinoma in situ) - 2019 update.Eur Urol. 2019; 76: 639-657
- Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis.Eur Urol Focus. 2018; 4: 558-567
- The impact of restaging transurethral resection of bladder tumor on survival parameters in T1 nonmuscle-invasive bladder cancer: systematic review and meta-analysis.J Endourol. 2020; 34: 795-804
- Assessing the quality of randomized trials: reliability of the Jadad scale.Contr Clin Trials. 1999; 20: 448-452
- The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.Bmj. 2011; 343: d5928
Wells, G.A., et al., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
- Methodological index for non-randomized studies (minors): development and validation of a new instrument.ANZ J Surg. 2003; 73: 712-716
- Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.J Urol. 1991; 146: 316-318
- Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?.J Urol. 2001; 165: 808-810
- Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?.Urology. 2002; 59: 220-223
- Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists.Urol Int. 2004; 72: 99-102
- A re-staging transurethral resection predicts early progression of superficial bladder cancer.BJU Int. 2006; 97: 1194-1198
- The value of a second transurethral resection for T1 bladder cancer.BJU Int. 2006; 97: 1199-1201
- T1 bladder cancer on restaging transurethral resection should be treated with immediate cystectomy.Indian J Urol. 2007; 23: 218
- Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?.J Urol. 2007; 177 (; discussion 79): 75-79
- Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.J Endourol. 2007; 21: 1533-1541
- Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature.J Endourol. 2008; 22: 2699-2704
- Complete transurethral resection of bladder tumor": are the guidelines being followed?.Urology. 2010; 75: 365-367
- Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer.J Endourol. 2010; 24: 2047-2050
- A prospective evaluation of second transurethral resection in non-muscle invasive bladder tumors.J buon. 2010; 15: 514-517
- The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.J Urol. 2010; 183: 2161-2164
- Is repeat transurethral resection effective and necessary in patients with T1 bladder carcinoma?.Urol Int. 2010; 85: 276-280
- Early re-resection for T1 transitional cell carcinoma of the bladder-A study of current practice in the South West of England.British Journal of Medical and Surgical Urology. 2011; 4: 18-23
- Second transurethral resection in T1G3 bladder tumors - selectively avoidable?.Indian J Urol. 2011; 27: 176-179
- An evaluation to define the role of repeat transurethral resection in a treatment algorithm for non-muscle-invasive bladder cancer.Indian J Urol. 2012; 28: 267-270
- Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection?.Urol Int. 2013; 91: 182-186
- Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.Jpn J Clin Oncol. 2013; 43: 404-409
- Predictive factors for residual tumor and tumor upstaging on relook transurethral resection of bladder tumor in non-muscle invasive bladder cancer.Urol Ann. 2014; 6: 305-308
- Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non-muscle-invasive bladder cancer. A step forward or back?.BJU Int. 2015; 115: 267-273
- Repeated transurethral resection for non-muscle invasive bladder cancer.Int J Clin Exp Med. 2015; 8: 1416-1419
- The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: results of a prospective study.Korean J Urol. 2015; 56: 429-434
- Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series.BJU Int. 2016; 117: 54-59
- Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta.Can Urol Assoc J. 2016; 10: 33-38
- Factors that predict residual tumors in re-TUR patients.Afr J Urol. 2016; 22: 67-70
- Can immediate second resection be an alternative to standardized second transurethral resection of bladder tumors?.Kaohsiung J Med Sci. 2016; 32: 147-151
- Prognostic impact of ReTURB in high grade T1 primary bladder cancer.Arch Ital Urol Androl. 2016; 88: 81-85
- Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?.Urol Oncol. 2017; 35: 603.e1-603.e5
- Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.Arch Ital Urol Androl. 2017; 89: 272-276
- Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.PLoS One. 2017; 12e0189354
- Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer.Eur Urol Focus. 2018; 4: 87-93
- Predictors of residual T1 high grade on Re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade 3 bladder cancer.J Cancer. 2018; 9: 4250-4254
- Recurrence and upstaging rates of T1 high-grade urothelial carcinoma of the bladder on repeat resection in a Canadian, resource-limited, healthcare system.Can Urol Assoc J. 2018; 12: 267-269
- Utility of restage transurethral resection of bladder tumor.Indian J Urol. 2018; 34: 273-277
- Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.Int J Urol. 2018; 25: 442-449
- Differences in pathologic results of repeat transurethral resection of bladder tumor (TURBT) according to institution performing the initial TURBT: comparative analyses between referred and nonreferred group.BioMed Res Int. 2018; (9432606)
- Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.World J Surg Oncol. 2018; 16: 6
- Predictive factors for residual cancer in second transurethral resection for non-muscle-invasive bladder cancer.Anticancer Res. 2019; 39: 4325-4328
- Second transurethral resection of bladder tumor: is it necessary in all T1 and/or high-grade tumors?.Urol J. 2019; 16: 152-156
- Identification of potential prognostic factors for absence of residual disease in the second resection of T1 bladder cancer.Cent European J Urol. 2019; 72: 252-257
- Effect of intravesical bacilli calmette-guerin therapy after second transurethral resection in stage Ta T1 high-grade bladder cancer.Yonago Acta Med. 2019; 62: 191-197
- Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.World J Urol. 2020; 38: 3161-3167
- Repeat transurethral resection is still an essential tool in treating non-muscle invasive bladder cancer: the Western Australian experience.Bladder (San Franc). 2020; 7: e42
- Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: a prospective study.Urol Oncol. 2020; 38: 935.e1-935.e8
- Restaging transurethral resection of bladder tumours after BCG immunotherapy induction in patients with T1 non-muscle-invasive bladder cancer might not Be associated with oncologic benefit.J Clin Med. 2020; 93306
- Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria.World J Urol. 2021; 39 (11th ed): 4159-4165
- Role of repeat transurethral resection of bladder tumours after primary resection: a retrospective cross-sectional study.J Clin Diagn Res. 2021; 15: PC06-PC08
- The result of re-transurethral resection of bladder tumor in eight years.J Med Assoc Thail. 2021; 104: 1411-1414
- Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study.J Urol. 2003; 170: 433-437
- The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer.Ecancermedicalscience. 2012; 6: 269
- The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.J Urol. 2014; 191: 341-345
- Results of second transurethral resection for high-grade T1 bladder cancer.Urol Ann. 2016; 8: 10-15
- Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.BMC Urol. 2016; 16: 8
- The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.BJU Int. 2016; 118: 44-52
- Second-look resection for primary stage T1 bladder cancer: a population-based study.Scand J Urol. 2017; 51: 301-307
- Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.Int J Clin Oncol. 2018; 23: 951-956
- Is repeat transurethral resection always needed in high-grade T1 bladder cancer?.Front Oncol. 2019; 9: 465
- Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years’ experience.Wideochir Inne Tech Maloinwazyjne. 2019; 14: 284-296
- Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience.Int Urol Nephrol. 2019; 51: 1335-1342
- Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer.Int J Urol. 2020; 27: 1130-1135
- The use of reTURB in T1 bladder cancer: a Norwegian population-based study.Scand J Urol. 2021; 55: 268-274
- A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer.Scand J Urol. 2021; 55: 108-115
- Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study.BJU Int. 2021; 129: 258-268
- Clinical outcomes of reresection in patients with high-risk nonmuscle-invasive bladder cancer treated with en bloc transurethral resection: a retrospective study with a 1-year follow-up.J Endourol. 2021; 35: 1801-1807
- The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial.Int J Clin Oncol. 2020; 25: 698-704
- Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline.J Urol. 2016; 196: 1021-1029
- Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations.Eur Urol. 2018; 74: 597-608
- CUA guidelines on the management of non-muscle invasive bladder cancer.Can Urol Assoc J. 2015; 9: E690-E704
Article info
Publication history
Published online: June 13, 2022
Accepted:
June 4,
2022
Received in revised form:
May 26,
2022
Received:
April 11,
2022
Identification
Copyright
© 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
